Drugs / Anisodamine
Anisodamine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02442440 | Apr 2015 → Oct 2020 | infectious disease with sepsis | Jinhua Central Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07657702 | Aug 2026 → Dec 2027 expected | infectious disease with sepsis | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| — | NCT05634057 | Jan 2024 → Dec 2025 overdue | infectious disease with sepsis | Chen Ying | Recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06045364 Comparator | Oct 2023 → Jul 2024 | — | Jie Chen | Completed | No outcome recorded |
| Phase 2 | NCT05727163 Background | Jul 2022 → Dec 2026 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT01929044 Comparator | Aug 2013 → Feb 2015 | intestinal disorder | Boehringer Ingelheim | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anisodamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727163 ↗ |
| Known as | (-)-6.beta.-hydroxyhyoscyamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2165224 ↗ |
| Known as | 654-II | “654-II (anisodamine)” NCT01929044 ↗ |
| Known as | Anisodamine hydrobromide | “Anisodamine hydrobromide injection + low molecular weight heparin + basic treatment” NCT05634057 ↗ |
| Action | Inhibit | “The efficacy of anisodamine might be mediated via the inhibition of thromboxane synthesis, granulocyte and platelet aggregation” NCT02442440 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Anisodamine is an agent extracted from traditional Chinese medicine with potent anti-inflammatory effects.” PMID 34579741 ↗ Sep 2021 |
| Route | Other | “Anisodamine (654-2) 10 mg HAI (Pre-chemotherapy)” NCT05727163 ↗ |